Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials – Supplementary Materials
Published: 2 April 2024| Version 1 | DOI: 10.17632/72j6brn9st.1
Contributors:
Mark Lebwohl, Joseph F. Merola, Bruce Strober, April Armstrong, Ayumi Yoshizaki, Paolo Gisondi, Balint Szilagyi, Luke Peterson, Dirk de Cuyper, Nancy Cross, Owen Davies, Alice B. GottliebDescription
Supplementary Materials for the manuscript titled 'Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials'. Includes a plain language summary (PLS) of the manuscript, a summary of hematology and biochemistry assessment schedules (Supplementary Table 1), EAIRs of laboratory elevations in ALT or AST >3x and >5x ULN with bimekizumab, placebo, and active comparators (Supplementary Table 2), and a summary of relevant medical history, concomitant medications, and confounding factors in patients with instances of laboratory elevations in ALT or AST >5x ULN (Supplementary Table 3).
Files
Categories
Clinical Trial, Liver, Biologicals, Psoriasis, Safety Assessment, Interleukin-17 Family
Funding
UCB Pharma